Nordeloz (Zoledronic Acid Monohydrate)

Zoledronic acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and blocks the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, leading to osteoclast apoptosis. This inhibition reduces bone breakdown and stabilises the skeletal matrix.

The specific dose and infusion schedule of Nordeloz are determined by the prescribing clinician based on the patient’s indication, renal function, and overall health. Healthcare providers follow approved guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for zoledronic acid in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the Nordeloz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Nordeloz (zoledronic acid) is a potent, once‑yearly intravenous bisphosphonate, offering higher binding affinity and longer skeletal residence than oral agents such as alendronate. This allows less frequent dosing but requires intravenous administration and monitoring for renal function, whereas oral bisphosphonates are taken daily or weekly with strict administration instructions.

Nordeloz should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before use, inspect the vial for any particulate matter or discoloration and handle with aseptic technique as recommended for intravenous preparations.

Nordeloz is given as an intravenous infusion, typically over 15 minutes, by a qualified healthcare professional. The infusion is performed in a clinical setting where vital signs can be monitored, and patients are observed for any acute reactions during and after the administration.

The most serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and acute severe hypocalcaemia. Patients should be educated on oral hygiene, report any jaw pain promptly, and have renal function and serum calcium checked regularly to mitigate these risks.

Nordeloz is contraindicated in patients with known hypersensitivity to zoledronic acid or any component of the formulation, in those with severe renal impairment (creatinine clearance <30 mL/min), and in individuals with untreated hypocalcaemia. Caution is also advised for patients with active dental problems or recent oral surgery.